Literature DB >> 31584779

Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials

Mohammed Dany.   

Abstract

Pyogenic granuloma (PG) is an acquired vascular growth on the skin and mucous membranes. Even though PG is a benign tumor, treatment is required due to associated risk of ulceration and bleeding, cosmetic concerns, and the low likelihood of spontaneous regression. Treatment entails excisional surgery, cryotherapy, or electrocautery; recurrence however is a major problem. Beta-blockers became an attractive option for the treatment of vascular growths after it got approved for infantile hemangioma. PG was found to express beta adrenergic receptors, similarly to infantile hemangioma. Several publications have reported the use of oral and topical beta blockers such as timolol, propranolol, and betaxolol for the treatment of PG. In this study, we summarized the literature with regards to the effectiveness of topical beta blockers for the treatment of PG, and discussed all published case reports, case series, and open-label single arm trials. J Drugs Dermatol. 2019;18(10):1006-1010.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31584779

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  Recurrent Significant Bleeding From Abdominal Wall Giant Pyogenic Granuloma Requiring Multiple Blood Transfusions.

Authors:  Mohamed Ahmed; Maya Itani; Ramsey Elsayed; Asef Bawahab; Yusef J Buti
Journal:  Cureus       Date:  2022-09-06

Review 2.  Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Authors:  Daniel J Yoon; Ramanjot Kaur; Anthony Gallegos; Kaitlyn West; Hsinya Yang; Saul Schaefer; Catherine Tchanque-Fossuo; Sara E Dahle; R Rivkah Isseroff
Journal:  Am J Clin Dermatol       Date:  2020-11-25       Impact factor: 7.403

3.  Topical timolol for the treatment of conjunctival pyogenic granulomas: Outcomes and effect on intraocular pressure.

Authors:  Akshay Gopinathan Nair; Ronnie Jacob George; Sundaram Natarajan; Vandana Jain
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.